Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Phase 2 Trials with Mgta-456, Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery in Patients Following Myeloablative or Non-Myeloablative Conditioning

John E. Wagner, MD, Claudio G Brunstein, MD PhD, Todd E. DeFor, MS, Anthony E. Boitano, PhD, David McKenna, MD, Darin Sumstad, MLS, Bastiano Sanna, Conrad Bleul, Michael P Cooke, PhD

Blood (2017) 130 (Supplement 1): 662.

https://doi.org/10.1182/blood.V130.Suppl_1.662.662

Published: 2017

Journal Articles

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

Jeffrey S. Miller, MD, Michael R. Verneris, MD, Julie Curtsinger, PhD, Todd E. DeFor, MS, David McKenna, MD, Thomas A Waldmann, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD, Sarah Cooley, MD

Blood (2015) 126 (23): 566.

https://doi.org/10.1182/blood.V126.23.566.566

Published: 2015

Journal Articles

StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Blood Transplantation (UCBT)

John E Wagner, MD, Claudio Brunstein, MD, David McKenna, MD, Darin Sumstad, MT(ASCP), Suzanne Maahs, Mary Laughlin, MD, Michael S. Perry, DVM,PhD, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Conrad C. Bleul, MD

Blood (2014) 124 (21): 728.

https://doi.org/10.1182/blood.V124.21.728.728

Published: 2014

Journal Articles

Safety and Exploratory Efficacy Of Ex Vivo Expanded Umbilical Cord Blood (UCB) Hematopoietic Stem and Progenitor Cells (HSPC) Using Cytokines and Stem-Regenin 1 (SR1): Interim Results Of a Phase 1/2 Dose Escalation Clinical Study

John E. Wagner, MD, Claudio G Brunstein, MD, David McKenna, MD, Darin Sumstad, MT(ASCP), Suzanne Maahs, Anthony E. Boitano, PhD, Michael P. Cooke, PhD, Conrad C. Bleul, MD

Blood (2013) 122 (21): 698.

https://doi.org/10.1182/blood.V122.21.698.698

Published: 2013

Journal Articles

Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML

Sarah Cooley, MD, Michael R. Verneris, MD, Julie Curtsinger, PhD, David McKenna, MD, Daniel J. Weisdorf, MD, Bruce R. Blazar, MD, Thomas A Waldmann, Jeffrey S. Miller, MD

Blood (2012) 120 (21): 894.

https://doi.org/10.1182/blood.V120.21.894.894

Published: 2012

Journal Articles

Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia

Sarah Cooley, Bree Foley, PhD, Michael R Verneris, MD, David McKenna, MD, Xianghua Luo, Kathryn E. Dusenbery, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD, Jeffrey S. Miller, MD

Blood (2011) 118 (21): 355.

https://doi.org/10.1182/blood.V118.21.355.355

Published: 2011

Journal Articles

IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,

Sarah Cooley, MD, Veronika Bachanova, Melissa Geller, MD, Michael R Verneris, MD, Bin Zhang, Valarie McCullar, David McKenna, MD, Dixie Lewis, Angela Panoskaltsis-Mortari, PhD, Daniel J. Weisdorf, MD, Philip McGlave, MD, Keli Hippen, Bruce R. Blazar, MD, Jeffrey S. Miller, MD

Blood (2011) 118 (21): 3611.

https://doi.org/10.1182/blood.V118.21.3611.3611

Published: 2011

Journal Articles

Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study

Hans-Georg Klingemann, MD, PhD, Carrie Grodman, RN, Andreas K. Klein, MD, Kellie Sprague, MD, Kenneth B. Miller, MD, Tarun Kewalramani, MD, Raymond L. Comenzo, MD, Neng Yu, MD, Marvin Duque, MD, Richard A. Van Etten, MD, PhD, David McKenna, MD

Blood (2010) 116 (21): 4299.

https://doi.org/10.1182/blood.V116.21.4299.4299

Published: 2010

Journal Articles

A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.

Jeffrey S. Miller, MD, Claudio G. Brunstein, MD, Sarah Cooley, MD, Michael R. Verneris, MD, Angela Panoskaltsis-Mortari, MD, Linda J. Burns, MD, David McKenna, MD, Kathryn Dusenbery, MD, Cladd Stevens, MD, Pablo Rubensten, MD, Marcie Tomblyn, MD, Mukta Arora, MD, Margaret L. MacMillan, MD, Todd DeFor, PhD, Chap Le, PhD, Philip B. McGlave, MD, Bruce R. Blazar, MD, Daniel J. Weisdorf, MD

Blood (2006) 108 (11): 3111.

https://doi.org/10.1182/blood.V108.11.3111.3111

Published: 2006

Journal Articles

The Impact of Variability among Banks on the Quality of Umbilical Cord Blood for Transplantation.

Jeffrey McCullough, MD, David McKenna, MD, Diane Kadidlo, BS, Therese Schierman, BS, John Wagner, MD

Blood (2004) 104 (11): 2861.

https://doi.org/10.1182/blood.V104.11.2861.2861

Published: 2004

Journal Articles

Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.

Jeffrey S. Miller, MD, Yvette Soignier, Angela Panosskaltsis-Mortari, PhD, David McKenna, MD, Chap Le, PhD, Todd E. Defor, PhD, Linda J. Burns, MD, Paul J. Orchard, MD, Bruce R. Blazar, MD, John E. Wagner, MD, Arne Slungaard, MD, Daniel J. Weisdorf, MD, Ian J. Okazaki, MD, Philip B. McGlave, MD

Blood (2004) 104 (11): 260.

https://doi.org/10.1182/blood.V104.11.260.260

Published: 2004

NARROW

Phase 2 Trials with Mgta-456, Single Cord Blood Units (CBU) Expanded with an Aryl Hydrocarbon Receptor (AHR) Antagonist, Demonstrate Uniform Engraftment and Rapid Hematopoietic Recovery in Patients Following Myeloablative or Non-Myeloablative Conditioning

A Phase I Study of Intravenous NCI IL-15 to Enhance Adoptively Transferred NK Cells Uncovers Defects in CD16 Triggered IFNγ Production and Competition Between Donor NK and Recipient T Cells

StemRegenin-1 (SR1) Expansion Culture Abrogates the Engraftment Barrier Associated with Umbilical Cord Blood Transplantation (UCBT)

Safety and Exploratory Efficacy Of Ex Vivo Expanded Umbilical Cord Blood (UCB) Hematopoietic Stem and Progenitor Cells (HSPC) Using Cytokines and Stem-Regenin 1 (SR1): Interim Results Of a Phase 1/2 Dose Escalation Clinical Study

Recombinant Human IL-15 Promotes in Vivo Expansion of Adoptively Transferred NK Cells in a First-in-Human Phase I Dose Escalation Study in Patients with AML

Haploidentical Natural Killer (NK) Cells Expanding In Vivo After Adoptive Transfer Exhibit Hyperfunction That Partially Overcomes Self Tolerance and Leads to Clearance of Refractory Leukemia

IL-2 Stimulated Treg Inhibit in Vitro Expansion of Haploidentical Natural Killer (NK) Cells, Which Is Partially Overcome with An IL-2-Diphtheria Toxin Fusion Protein In Vivo,

Allogeneic NK Cell Therapy After Autologous Stem Cell Transplant: Results of a Phase I Study

A Novel Triple Umbilical Cord Blood Transplant (UCBT) Strategy To Promote NK Cell Immunotherapy (Unit 1) with a Fully Ablative Preparative Regimen Followed by a Double UCBT in Patients with Refractory AML.

The Impact of Variability among Banks on the Quality of Umbilical Cord Blood for Transplantation.

Successful Remission of Poor Prognosis AML after Adoptive Transfer and In Vivo Expansion of Human Haploidentical NK Cells.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only